Bing Lu
Impact in
- Virology top 5%
- HIV Research and Treatment
- Infectious Diseases top 5%
- HIV/AIDS drug development and treatment
Papers in
-
- HIV/AIDS drug development and treatment 9
-
- Pharmacogenetics and Drug Metabolism 6
- Co-authors
- Wei Zhao (11 shared papers)Xiaojia Huang (3 shared papers)Jingxin Mo (2 shared papers)Changye Zou (5 shared papers)Jincan He (3 shared papers)Yangyang He (2 shared papers)Jiaming Yu (3 shared papers)Meiling Yang (2 shared papers)
- Journals
- Cell Death and Disease (3 papers)ACS Medicinal Chemistry Letters (2 papers)Nature (2 papers)Frontiers in Pharmacology (2 papers)Antimicrobial Agents and Chemotherapy (2 papers)
- Partner nations
- United StatesChinaSweden
In The Last Decade
Bing Lu
30 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 73
- Virology 153
- Infectious Diseases 286
- Biomaterials 78
- Pharmacology 51
- Oncology 115
Countries citing papers authored by Bing Lu
This map shows the geographic impact of Bing Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bing Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bing Lu more than expected).
Fields of papers citing papers by Bing Lu
This network shows the impact of papers produced by Bing Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bing Lu. The network helps show where Bing Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Bing Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 329 | |
| 2 | 2021 | 77 | |
| 3 | 2021 | 76 | |
| 4 | 2016 | 68 | |
| 5 | 2013 | 61 | |
| 6 | 2020 | 56 | |
| 7 | 2018 | 50 | |
| 8 | 2017 | 47 | |
| 9 | 2003 | 44 | |
| 10 | 2019 | 40 | |
| 11 | 2024 | 35 | |
| 12 | 2019 | 33 | |
| 13 | 2015 | 31 | |
| 14 | 2006 | 26 | |
| 15 | 2023 | 24 | |
| 16 | 2021 | 22 | |
| 17 | 2022 | 22 | |
| 18 | 2021 | 20 | |
| 19 | 2004 | 18 | |
| 20 | 2011 | 17 |
About Bing Lu
Bing Lu is a scholar working on Infectious Diseases, Pharmacology, Virology, Hepatology and Oncology, having authored 31 papers that have together received 1.2k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (9 papers), Pharmacogenetics and Drug Metabolism (6 papers), Hepatitis C virus research (4 papers), HIV Research and Treatment (4 papers), Sarcoma Diagnosis and Treatment (4 papers), Nanoparticle-Based Drug Delivery (3 papers), Cancer Cells and Metastasis (3 papers) and Genomics and Chromatin Dynamics (3 papers). The work is most often cited by research in Virology (153 citations), Infectious Diseases (286 citations), Biomaterials (78 citations), Pharmacology (51 citations) and Oncology (115 citations). Bing Lu has collaborated with scholars based in United States, China and Sweden. Frequent co-authors include Wei Zhao, Xiaojia Huang, Jingxin Mo, Changye Zou, Jincan He, Yangyang He, Jiaming Yu, Meiling Yang, Jun Wu and Angelo Paradiso. Their work appears in journals such as Cell Death and Disease, ACS Medicinal Chemistry Letters, Nature, Frontiers in Pharmacology and Antimicrobial Agents and Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.